Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 14, 2014; 20(38): 13741-13755
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13741
Table 2 Clinical trials of sunitinib
PatientsPhaseTreatmentnOS (m)PFS (m)TTP (m)RRDCR
Pretreated patients with advanced gastric cancerIISunitinib515.81.28N/A3.9%20.0%
Second line treatment for advanced gastric cancerIISunitinib786.82.32.32.6%34.7%
Unresectable or metastatic advanced gastric cancer after failed treatment with fluoropyrimidine + platinumIIDocetaxel496.6N/A2.614.3%51.0%
Docetaxel + sunitinib568.0N/A3.941.1%75.0%